Biogen CEO Pick Vounatsos Suggests A Return To Commercial Focus
Executive Summary
Biogen’s Chief Commercial Officer Michel Vounatsos will succeed CEO George Scangos effective Jan. 6. The appointment of the longtime Merck executive appears to suggest a renewed emphasis on the commercial landscape for a big biotech that has recently played up R&D.
You may also be interested in...
Inexperienced Biotech CEOs Impact Investor Confidence – Analyst Research
Median tenure of large cap US biotech CEOs has decreased from 11 years in 2007 to one year in 2017, Leerink analyst Geoffrey Porges determined in an analysis of seven biotechs over 15 years.
Biogen Staying "Laser-Focused" On Neuroscience
The company is under pressure from investors to add new pipeline assets, but stronger than expected initial sales of Spinraza helped to assuage near-term growth concerns.
Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal
Biogen agreed to pay $300m upfront to buy a Phase II-ready tau antibody from Bristol. The plan is to move rapidly into mid-stage clinical trials for Alzheimer's disease and progressive supranuclear palsy.